Innovative agents in marginal zone lymphoma and other B-cell malignancies
Innovative agents in marginal zone lymphoma and
Exploring chemotherapy-free approaches in the treatment of DLBCL
Exploring chemotherapy-free approaches in the tr
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies
Updated findings in CLL with a focus on BTK- and
Follicular lymphoma: BTK inhibition and bispecific antibodies
Follicular lymphoma: BTK inhibition and bispecif
Improving responses in multiple myeloma
Improving responses in multiple myeloma PERS
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Waldenström macroglobulinemia: optimizing outcom
Mantle cell lymphoma: emerging treatment regimens and new standards
Mantle cell lymphoma: emerging treatment regimen
Preface – ASH 2023
Preface – ASH 2023 © private – Moritz Fürste
